This is just part of the article that mentions OCAT !!
Mako Research has also posted blog posts recently attacking a Marlborough-based biotech working on treatments for some types of blindness, called Ocata Therapeutics (Nasdaq: OCAT). CEO Paul Wotton declined to comment on the blog posts last week, which made many claims similar to those made against Cellceutix.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.